



FINANCIAL TEAR SHEET

CORPORATE PROFILE

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

STOCK INFORMATION

CHRS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$17.20
Change (%)	▲ 0.90 (5.52%)
Volume	2,500,129
52 Week Low	\$8.05
Market Cap	\$1,123,618,174
Rolling EPS	-3.68
PE Ratio	N/A
Shares Outstanding	65,326,638

Data as of 06/22/18 4:00 p.m. ET



RECENT NEWS & UPCOMING EVENTS

- 06/22/18 [Coherus BioSciences Announces New Employment Inducement Grants](#)
- 05/25/18 [Coherus BioSciences Announces New Employment Inducement Grants](#)
- 05/22/18 [Coherus Prices Public Offering of Common Stock](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
06/21/18	<u>CTORDER</u>
06/20/18	<u>4</u>
06/14/18	<u>S-8</u>
05/29/18	<u>8-K</u>

CORPORATE GOVERNANCE

<u>Denny Lanfear</u>	President, CEO and Chairman
<u>Barbara Finck, M.D.</u>	Chief Medical Officer
<u>Alan Herman, Ph.D.</u>	Chief Scientific Officer
<u>Jean-Frederic Viret, Ph.D.</u>	Chief Financial Officer
<u>Peter Watler, Ph.D.</u>	Chief Technical Officer
<u>Vince Anicetti</u>	SVP, Global Quality
<u>Lisa M. Bell, Ph.D.</u>	SVP, Regulatory Affairs
<u>Michael Fleming</u>	SVP, Commercial Strategy
<u>Matthew R. Hooper</u>	SVP, General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.